• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 蛋白酶抑制剂的筛选、合成和生化特性分析。

Screening, Synthesis and Biochemical Characterization of SARS-CoV-2 Protease Inhibitors.

机构信息

Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, LT-10257 Vilnius, Lithuania.

Department of Microbiology and Biotechnology, Institute of Biosciences, Life Sciences Center, Vilnius University, Saulėtekio 7, LT-10257 Vilnius, Lithuania.

出版信息

Int J Mol Sci. 2023 Aug 30;24(17):13491. doi: 10.3390/ijms241713491.

DOI:10.3390/ijms241713491
PMID:37686295
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10488051/
Abstract

The severe acute respiratory syndrome-causing coronavirus 2 (SARS-CoV-2) papain-like protease (PL) and main protease (M) play an important role in viral replication events and are important targets for anti-coronavirus drug discovery. In search of these protease inhibitors, we screened a library of 1300 compounds using a fluorescence thermal shift assay (FTSA) and identified 53 hits that thermally stabilized or destabilized PL. The hit compounds structurally belonged to two classes of small molecules: thiazole derivatives and symmetrical disulfide compounds. Compound dissociation constants (K) were determined using an enzymatic inhibition method. Seven aromatic disulfide compounds were identified as efficient PL inhibitors with K values in the micromolar range. Two disulfides displayed six-fold higher potency for PL (K = 0.5 µM) than for M. The disulfide derivatives bound covalently to both proteases, as confirmed through mass spectrometry. The identified compounds can serve as lead compounds for further chemical optimization toward anti-COVID-19 drugs.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)木瓜蛋白酶样蛋白酶(PL)和主要蛋白酶(M)在病毒复制事件中发挥重要作用,是抗冠状病毒药物发现的重要靶点。为了寻找这些蛋白酶抑制剂,我们使用荧光热转移分析(FTSA)筛选了 1300 种化合物库,鉴定出 53 种能够热稳定或不稳定 PL 的化合物。这些命中化合物在结构上属于两类小分子:噻唑衍生物和对称二硫化物化合物。使用酶抑制方法测定化合物的解离常数(K)。确定了 7 种芳香族二硫化物化合物是有效的 PL 抑制剂,其 K 值在微摩尔范围内。两种二硫化物对 PL(K=0.5µM)的效力比 M 高六倍。通过质谱证实,二硫化物衍生物与两种蛋白酶均以共价键结合。鉴定出的化合物可作为进一步化学优化以开发抗 COVID-19 药物的先导化合物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/d14c85a99f0d/ijms-24-13491-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/61cd7674bfb2/ijms-24-13491-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/76ffb442fb08/ijms-24-13491-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/529aac1ac8d9/ijms-24-13491-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/e1150dac923f/ijms-24-13491-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/aa249ae8afc7/ijms-24-13491-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/027d2231307d/ijms-24-13491-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/7232df44e189/ijms-24-13491-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/003d8ad15e03/ijms-24-13491-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/d14c85a99f0d/ijms-24-13491-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/61cd7674bfb2/ijms-24-13491-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/76ffb442fb08/ijms-24-13491-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/529aac1ac8d9/ijms-24-13491-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/e1150dac923f/ijms-24-13491-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/aa249ae8afc7/ijms-24-13491-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/027d2231307d/ijms-24-13491-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/7232df44e189/ijms-24-13491-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/003d8ad15e03/ijms-24-13491-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a25/10488051/d14c85a99f0d/ijms-24-13491-g009.jpg

相似文献

1
Screening, Synthesis and Biochemical Characterization of SARS-CoV-2 Protease Inhibitors.SARS-CoV-2 蛋白酶抑制剂的筛选、合成和生化特性分析。
Int J Mol Sci. 2023 Aug 30;24(17):13491. doi: 10.3390/ijms241713491.
2
Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M and Papain-like Protease PL of SARS-CoV-2.基于结构的新型 SARS-CoV-2 主要蛋白酶 M 和木瓜蛋白酶样蛋白酶 PL 抑制剂萘醌及其衍生物的鉴定。
J Chem Inf Model. 2022 Dec 26;62(24):6553-6573. doi: 10.1021/acs.jcim.2c00693. Epub 2022 Aug 12.
3
High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.高通量筛选 SARS-CoV-2 主蛋白酶和木瓜蛋白酶样蛋白酶抑制剂。
Protein Cell. 2022 Sep 28;14(1):17-27. doi: 10.1093/procel/pwac016. eCollection 2023 Jan.
4
Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.质谱分析揭示了 SARS-CoV-2 木瓜蛋白酶样蛋白酶抑制剂特性的差异。
ChemMedChem. 2022 May 4;17(9):e202200016. doi: 10.1002/cmdc.202200016. Epub 2022 Feb 17.
5
Analysis of the Antidepressant Fluoxetine and Related Drugs at SARS-CoV-2 Main Protease (M) and Papain-like Protease (PL).分析抗抑郁药氟西汀和相关药物在 SARS-CoV-2 主蛋白酶(M)和木瓜蛋白酶样蛋白酶(PL)上的作用。
Curr Drug Discov Technol. 2023;20(2):e101022209771. doi: 10.2174/1570163819666221010115118.
6
Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.建立基于模拟的计算管道,以寻找针对 SARS-CoV-2 木瓜蛋白酶样蛋白酶的新型抑制性支架。
Molecules. 2021 Feb 20;26(4):1134. doi: 10.3390/molecules26041134.
7
Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.小分子与 SARS-CoV-2 木瓜蛋白酶样蛋白酶的相互作用:使用酶抑制测定法进行的体外验证和体外验证蛋白酶活性抑制的计算研究。
J Mol Graph Model. 2021 May;104:107851. doi: 10.1016/j.jmgm.2021.107851. Epub 2021 Jan 26.
8
Structure-based design of SARS-CoV-2 papain-like protease inhibitors.基于结构的 SARS-CoV-2 木瓜蛋白酶样蛋白酶抑制剂设计。
Eur J Med Chem. 2024 Jan 15;264:116011. doi: 10.1016/j.ejmech.2023.116011. Epub 2023 Dec 5.
9
Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors.来源于 Bothropstoxin-I 的非毒性二聚体肽是有效的 SARS-CoV-2 和木瓜蛋白酶样蛋白酶抑制剂。
Molecules. 2021 Aug 12;26(16):4896. doi: 10.3390/molecules26164896.
10
A Patent Review on SARS Coronavirus Papain-Like Protease (PL ) Inhibitors.SARS 冠状病毒木瓜蛋白酶样蛋白酶(PL )抑制剂的专利研究综述。
ChemMedChem. 2023 Aug 15;18(16):e202300216. doi: 10.1002/cmdc.202300216. Epub 2023 Jun 15.

引用本文的文献

1
Hydrogen sulfide (H2S) coordinates redox balance, carbon metabolism, and mitochondrial bioenergetics to suppress SARS-CoV-2 infection.硫化氢(H2S)协调氧化还原平衡、碳代谢和线粒体生物能量学以抑制新型冠状病毒2(SARS-CoV-2)感染。
PLoS Pathog. 2025 May 19;21(5):e1013164. doi: 10.1371/journal.ppat.1013164. eCollection 2025 May.

本文引用的文献

1
Thermal unfolding methods in drug discovery.药物发现中的热展开方法。
Biophys Rev (Melville). 2023 May 16;4(2):021305. doi: 10.1063/5.0144141. eCollection 2023 Jun.
2
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China.从实验室到病床:中国小分子抗 SARS-CoV-2 药物的创新。
Eur J Med Chem. 2023 Sep 5;257:115503. doi: 10.1016/j.ejmech.2023.115503. Epub 2023 May 18.
3
Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.补体与 COVID-19:三年过去了,我们知道了什么,不知道什么,以及我们应该知道什么。
Immunobiology. 2023 May;228(3):152393. doi: 10.1016/j.imbio.2023.152393. Epub 2023 May 11.
4
Therapeutic strategies for COVID-19: progress and lessons learned.COVID-19 的治疗策略:进展与经验教训。
Nat Rev Drug Discov. 2023 Jun;22(6):449-475. doi: 10.1038/s41573-023-00672-y. Epub 2023 Apr 19.
5
COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies.2023年初的新型冠状病毒肺炎:严重急性呼吸综合征冠状病毒2的结构、复制机制、变体、诊断测试以及疫苗与药物研发研究
MedComm (2020). 2023 Apr 8;4(2):e228. doi: 10.1002/mco2.228. eCollection 2023 Apr.
6
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease.COVID-19 治疗药物:针对 SARS-CoV-2 主蛋白酶的小分子药物研发。
Drug Discov Today. 2023 Jun;28(6):103579. doi: 10.1016/j.drudis.2023.103579. Epub 2023 Apr 5.
7
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.可传播的对临床蛋白酶抑制剂具有耐药性的 SARS-CoV-2 变异株。
Sci Adv. 2023 Mar 29;9(13):eade8778. doi: 10.1126/sciadv.ade8778.
8
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2.强效且选择性抑制 SARS-CoV-2 的木瓜蛋白酶样蛋白酶。
Nat Commun. 2023 Mar 28;14(1):1733. doi: 10.1038/s41467-023-37254-w.
9
Therapeutic developments for SARS-CoV-2 infection-Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的治疗进展——抗病毒药物的作用分子机制及临床实践中应对新出现变异株耐药性的策略
Front Microbiol. 2023 Mar 2;14:1132501. doi: 10.3389/fmicb.2023.1132501. eCollection 2023.
10
A new generation M inhibitor with potent activity against SARS-CoV-2 Omicron variants.一种对 SARS-CoV-2 奥密克戎变异株具有强大活性的新型 M 抑制剂。
Signal Transduct Target Ther. 2023 Mar 16;8(1):128. doi: 10.1038/s41392-023-01392-w.